These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 31345074)

  • 21. Magmaris™ resorbable magnesium scaffold: state-of-art review.
    Cerrato E; Barbero U; Gil Romero JA; Quadri G; Mejia-Renteria H; Tomassini F; Ferrari F; Varbella F; Gonzalo N; Escaned J
    Future Cardiol; 2019 Jul; 15(4):267-279. PubMed ID: 31084216
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of everolimus-eluting bioresorbable vascular scaffolds versus durable polymer everolimus-eluting metallic stents assessed at 1-year follow-up: A systematic review and meta-analysis of studies.
    Mukete BN; van der Heijden LC; Tandjung K; Baydoun H; Yadav K; Saleh QA; Doggen CJ; Abi Rafeh N; Le Jemtel TH; von Birgelen C
    Int J Cardiol; 2016 Oct; 221():1087-94. PubMed ID: 27448538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.
    Puricel S; Arroyo D; Corpataux N; Baeriswyl G; Lehmann S; Kallinikou Z; Muller O; Allard L; Stauffer JC; Togni M; Goy JJ; Cook S
    J Am Coll Cardiol; 2015 Mar; 65(8):791-801. PubMed ID: 25720622
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial.
    Serruys PW; Chevalier B; Dudek D; Cequier A; Carrié D; Iniguez A; Dominici M; van der Schaaf RJ; Haude M; Wasungu L; Veldhof S; Peng L; Staehr P; Grundeken MJ; Ishibashi Y; Garcia-Garcia HM; Onuma Y
    Lancet; 2015 Jan; 385(9962):43-54. PubMed ID: 25230593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents.
    Han Y; Xu B; Fu G; Wang X; Xu K; Jin C; Tao L; Li L; Hou Y; Su X; Fang Q; Chen L; Liu H; Wang B; Yuan Z; Gao C; Zhou S; Sun Z; Zhao Y; Guan C; Stone GW;
    JACC Cardiovasc Interv; 2018 Feb; 11(3):260-272. PubMed ID: 29413240
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second-Generation Drug-Eluting Resorbable Magnesium Scaffold: Review of the Clinical Evidence.
    Ozaki Y; Garcia-Garcia HM; Shlofmitz E; Hideo-Kajita A; Waksman R
    Cardiovasc Revasc Med; 2020 Jan; 21(1):127-136. PubMed ID: 31662277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neointimal Healing Evaluated by Optical Coherence Tomography after Drug-Eluting Absorbable Metal Scaffold Implantation in de novo Native Coronary Lesions: Rationale and Design of the Magmaris-OCT Study.
    Karjalainen P; Paana T; Sia J; Nammas W
    Cardiology; 2017; 137(4):225-230. PubMed ID: 28467998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro and in vivo evaluation of a novel bioresorbable magnesium scaffold with different surface modifications.
    Menze R; Wittchow E
    J Biomed Mater Res B Appl Biomater; 2021 Sep; 109(9):1292-1302. PubMed ID: 33386677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de-novo coronary artery lesions (BIOSOLVE-II): 6 month results of a prospective, multicentre, non-randomised, first-in-man trial.
    Haude M; Ince H; Abizaid A; Toelg R; Lemos PA; von Birgelen C; Christiansen EH; Wijns W; Neumann FJ; Kaiser C; Eeckhout E; Lim ST; Escaned J; Garcia-Garcia HM; Waksman R
    Lancet; 2016 Jan; 387(10013):31-9. PubMed ID: 26470647
    [TBL] [Abstract][Full Text] [Related]  

  • 30. One- and two-year clinical outcomes of treatment with resorbable magnesium scaffolds for coronary artery disease: the prospective, international, multicentre BIOSOLVE-IV registry.
    Wlodarczak A; Montorsi P; Torzewski J; Bennett J; Starmer G; Buck T; Haude M; Moccetti M; Wiemer M; Lee MK; Verheye S
    EuroIntervention; 2023 Jun; 19(3):232-239. PubMed ID: 37226676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The 1-Year Safety and Efficacy Outcomes of Magmaris, Novel Magnesium Bioresorbable Vascular Scaffolds in Diabetes Mellitus Patients with Acute Coronary Syndrome.
    Włodarczak A; Łanocha M; Szudrowicz M; Barycki M; Gosiewska A; Kulczycki JJ; Lesiak M; Doroszko A; Rola P
    J Clin Med; 2021 Jul; 10(14):. PubMed ID: 34300332
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Magnesium bioresorbable scaffold (Magmaris) versus polymer biodegradable ultrathin drug-eluting stent (Ultimaster) in acute coronary syndrome. Mid-term outcomes (2 years).
    Włodarczak A; Rola P; Włodarczak S; Szudrowicz M; Jaroszewska-Pozorska J; Barycki M; Furtan Ł; Kędzierska M; Doroszko A; Lesiak M
    Postepy Kardiol Interwencyjnej; 2024 Mar; 20(1):67-75. PubMed ID: 38616930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Magmaris: a new generation metallic sirolimus-eluting fully bioresorbable scaffold: present status and future perspectives.
    Rapetto C; Leoncini M
    J Thorac Dis; 2017 Aug; 9(Suppl 9):S903-S913. PubMed ID: 28894596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioresorbable Scaffold: The Emerging Reality and Future Directions.
    Sotomi Y; Onuma Y; Collet C; Tenekecioglu E; Virmani R; Kleiman NS; Serruys PW
    Circ Res; 2017 Apr; 120(8):1341-1352. PubMed ID: 28408454
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanical properties of the drug-eluting bioresorbable magnesium scaffold compared with polymeric scaffolds and a permanent metallic drug-eluting stent.
    Barkholt TØ; Webber B; Holm NR; Ormiston JA
    Catheter Cardiovasc Interv; 2020 Dec; 96(7):E674-E682. PubMed ID: 31710149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term results of BVS implantation: a focus on safety and efficacy of the bioresorbable technology.
    DEN Dekker WK; VAN Geuns RJ; Diletti R
    Minerva Cardioangiol; 2016 Aug; 64(4):462-72. PubMed ID: 27175976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioresorbable Vascular Scaffolds for Coronary Revascularization.
    Kereiakes DJ; Onuma Y; Serruys PW; Stone GW
    Circulation; 2016 Jul; 134(2):168-82. PubMed ID: 27400899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Temporal Trends in Adverse Events After Everolimus-Eluting Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: A Meta-Analysis of Randomized Controlled Trials.
    Montone RA; Niccoli G; De Marco F; Minelli S; D'Ascenzo F; Testa L; Bedogni F; Crea F
    Circulation; 2017 May; 135(22):2145-2154. PubMed ID: 28559495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.
    Mahmoud AN; Barakat AF; Elgendy AY; Schneibel E; Mentias A; Abuzaid A; Elgendy IY
    Circ Cardiovasc Interv; 2017 May; 10(5):. PubMed ID: 28468954
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bioresorbable metal scaffold for cardiovascular application: current knowledge and future perspectives.
    Kitabata H; Waksman R; Warnack B
    Cardiovasc Revasc Med; 2014 Mar; 15(2):109-16. PubMed ID: 24684760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.